Navigation Links
Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
Date:12/2/2011

ROCHESTER, Minn. -- Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

NMO is an inflammatory autoimmune disease of the central nervous system that damages the optic nerves and spinal cord, causing vision loss, weakness, numbness and, sometimes, arm and leg paralysis and loss of bowel and bladder control. NMO was historically misdiagnosed as a severe variant of MS until 2005 when a team led by Vanda A. Lennon, M.D., Ph.D., a Mayo Clinic research immunologist, identified an antibody unique to NMO, and discovered that its unexpected target was the major water channel of the central nervous system (aquaporin-4). A blood test emerging from this discovery has revolutionized the diagnosis of NMO, allowing its distinction from multiple sclerosis and introducing more appropriate treatments.

The NMO antibody targets astrocytes, which are 10 times more numerous in the brain and spinal cord than neurons. In addition to providing nutrients to neurons and supporting the repair and scarring process, other critical functions of astrocytes include regulation of tissue water and electrical activities of neurons, and the stabilizing the protective covering of nerves (myelin). By attacking the water channels on astrocytes, the antibody disrupts all related dynamic functions of the astrocyte and in acute attacks kills many astrocytes.

The new findings advance the understanding of the basic mechanisms of NMO, critical to the ultimate development of optimal treatment or even a cure. Key findings include:

  • The antibody associated with NMO affects two forms of the aquaporin-4 water channel: M1 and M23. M1 more readily escapes from antibodies, but antibody binding to M23 causes aggregation of M23 on the astrocyte surface which amplifies cell damage.
  • As a consequence of antibody interfering with the transfer of water in the brain, water accumulates in the myelin sheath, preventing rapid transmission of nerve messages) and causing breakdown of myelin, a traditional hallmark of MS, thus contributing to the diagnostic confusion.
  • Traditional therapies used to treat MS may actually make NMO worse.

"These findings build on our initial research and greatly advance our understanding of disease development and progression in patients with NMO," Dr. Lennon says. "Only by learning more about NMO can we develop new therapies and new approaches to treat people with this terrible disease."

About Neuromyelitis Optica

Because NMO has only recently been identified as a syndrome distinct from MS, it is difficult to know how many people have it. To date the Mayo Clinic Neuroimmunology Laboratory has detected the antibody in three thousand patients in the United States. Thus NMO is more common than was previously thought. Disease progresses with each new attack, and there is no cure. For most patients, a combination of drug and physical therapy is required to manage NMO, with the focus being on preventing recurrent attacks after treatment of the first attack, thus reducing disability and preventing relapses.


'/>"/>

Contact: Brian Kilen
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Newly established neuroscience clinical trials center could bring treatments to patients faster
2. 2011 ASH Annual Meeting to highlight latest hematology research, clinical care breakthroughs
3. BMC resident receives American Society for Clinical Pathology awards
4. First whole-genome sequencing clinical trials for triple-negative breast cancer presented
5. Researchers validate preclinical effectiveness of TB drug target
6. Use of retail medical clinics rises 10-fold over 2-year period, study finds
7. AAOS issues new clinical practice guideline for treating common elbow fractures in children
8. First MacLean Center Prize in Clinical Ethics awarded to Dartmouths John Wennberg
9. New screening method can detect a range of clinical conditions from a single dried blood spot
10. CDC and Prevention awards Mayo Clinic an international medical education grant
11. Mayo Clinic study confirms smoke-free workplaces reduce heart attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology: